MDMA interactions with pharmaceuticals and drugs of abuse

References

• Rekić D, Reynolds KS, Zhao P, et al. Clinical drug-drug interaction evaluations to inform drug use and enable drug access. J Pharm Sci. 2017;106:2214‒2218. .
   Google Scholar
• United Nations Office on Drugs and Crim (UNDOC). World Drug Report 2011. [cited 2020 Jan 29]. Available from: https://www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2017: trends and developments. [cited 2020 Jan 29]. Available from: http://www.emcdda.europa.eu/system/files/publications/4541/TDAT17001ENN.pdf
   Google Scholar
• United Nations Office on Drugs and Crim (UNDOC). UN convention on psychotropic substances; 1971. [cited 2020 Jan 29]. Availabe from: https://www.unodc.org/pdf/convention_1971_en.pdf
   Google Scholar
• United Nations Office on Drugs and Crime (UNDOC). World drug report 2019. [cited 2020 Jan 29]. Available from: https://wdr.unodc.org/wdr2019/index.html
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2019: trends and Developments. [cited 2020 Jan 29]. Available from: http://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf
   Google Scholar
• Vermetten E, Yehuda R. MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment. Neuropsychopharmacology. 2020;45:231‒232.
   Google Scholar
• Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther. 2011;90:246‒255.
   Google Scholar
• Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168:458‒470.
   Google Scholar
• Verrico CD, Miller GM, Madras BK. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl). 2007;189:489‒503.
   Google Scholar
• White SR, Obradovic T, Imel KM. The effects of methylenedioxymethamphetamine (MDMA, “Ecstasy”) on monoaminergic neurotransmission in the central nervous system. ProgNeurobiol. 1996;49:455‒479.
   Google Scholar
• Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly. 2015;145:w14043.
   Google Scholar
• de la Torre R, Farré M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26:137‒144.
   Google Scholar
• Pizarro N, Ortuño J, Farré M, et al. Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol. 2002;26: 157‒165. PubMed PMID: 11991532.
   Google Scholar
• Perfetti X, O’Mathúna B, Pizarro N, et al. Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab Dispos. 2009;37:1448‒1455.
   Google Scholar
• O’Mathúna B, Farré M, Rostami-Hodjegan A, et al. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol. 2008;28:523‒5299.
   Google Scholar
• Farré M, de la Torre R, Mathúna BO, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl). 2004;173:364‒375.
   Google Scholar
• de la Torre R, Farré M, Ortuño J, et al. Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans. Br J Clin Pharmacol. 2000;49:104‒109.
   Google Scholar
• Schmid Y, Vizeli P, Hysek CM, et al. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals. Pharmacogenet Genomics. 2016;26:397‒401.
   Google Scholar
• Vizeli P, Schmid Y, Prestin K, et al. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. EurNeuropsychopharmacol. 2017;27:232‒238.
   Google Scholar
• Vizeli P, Meyer ZuSchwabedissen HE, Liechti ME. Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects. ACS Chem Neurosci. 2019;10:3120‒3131.
   Google Scholar
• Vizeli P, Meyer ZuSchwabedissen HE, Liechti ME. No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA. Eur J Clin Pharmacol. 2018;74:275‒283.
   Google Scholar
• Vizeli P, Liechti ME. Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects. PLoS One. 2018;13:e0199384.
   Google Scholar
• Cami J, Farré M, Mas M, et al. Human pharmacology of 3,4methylenedioxymethamphetamine (“ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000;20:455‒466.
   Google Scholar
• de la Torre R, Farré M, Roset PN, et al. Pharmacology of MDMA in humans. Ann N Y Acad Sci. 2000;914:225‒237.
   Google Scholar
• Mas M, Farré M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136‒145.
   Google Scholar
• Farré M, Tomillero A, Pérez-Mañá C, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart. EurNeuropsychopharmacol. 2015;25:1637‒1649.
   Google Scholar
• Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31:576‒588.
   Google Scholar
• Papaseit E, Pérez-Mañá C, Mateus JA, et al. Human pharmacology of mephedrone in comparison with MDMA. Neuropsychopharmacology. 2016;41:2704‒2713.
   Google Scholar
• Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001;154:161‒168.
   Google Scholar
• Green AR, Mechan AO, Elliott JM, et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev. 2003;55:463‒508.
   Google Scholar
• Kamilar-Britt P, Bedi G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci Biobehav Rev. 2015;57:433‒446.
   Google Scholar
• Kirkpatrick MG, de Wit H. MDMA: a social drug in a social context. Psychopharmacology (Berl). 2015;232:1155‒1563.
   Google Scholar
• Hysek CM, Schmid Y, Simmler LD, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9:1645‒1652.
   Google Scholar
• Papaseit E, Torrens M, Pérez-Mañá C, et al. Key interindividual determinants in MDMA pharmacodynamics. Expert Opin Drug Metab Toxicol. 2018;14:183‒195.
   Google Scholar
• Armenian P, Mamantov TM, Tsutaoka BT, et al. Multiple MDMA (Ecstasy) overdoses at a rave event: a case series. J Intensive Care Med. 2013;28:252‒258.
   Google Scholar
• Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol. 2012;86:1167‒1231.
   Google Scholar
• Halpern P, Moskovich J, Avrahami B, et al. Morbidity associated with MDMA (ecstasy) abuse: a survey of emergency department admissions. Hum Exp Toxicol. 2011;30:259‒266.
   Google Scholar
• Vakde T, Diaz M, Uday K, et al. Rapidly reversible multiorgan failure after ingestion of “Molly” (pure 3,4-methylenedioxymethamphetamine): a case report. J Med Case Rep. 2014;8:204.
   Google Scholar
• Kahn DE, Ferraro N, Benveniste RJ. 3 cases of primary intracranial hemorrhage associated with “Molly”, a purified form of 3,4-methylenedioxymethamphetamine(MDMA). J Neurol Sci. 2012;323(1–2):257‒260.
   Google Scholar
• Montastruc F, Montastruc G, Vigreux P, et al. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Br J Clin Pharmacol. 2012;74:547‒548.
   Google Scholar
• Baumann MH, Rothman RB. Neural and cardiac toxicities associated with3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol. 2009;88:257‒296.
   Google Scholar
• Sano R, Hasuike T, Nakano M, et al. A fatal case of myocardial damage due to misuse of the “designer drug” MDMA. Leg Med (Tokyo). 2009 Nov;11(6):294‒297. .
   Google Scholar
• Mortelmans LJ, Bogaerts PJ, Hellemans S, et al. Spontaneous pneumomediastinum and myocarditis following Ecstasy use: a case report. Eur J Emerg Med. 2005;12:36‒38.
   Google Scholar
• Auer J, Berent R, Weber T, et al. Subarachnoid haemorrhage with”Ecstasy” abuse in a young adult. Neurol Sci. 2002;23:199‒201.
   Google Scholar
• Alciati A, Scaramelli B, Fusi A, et al. Three cases of delirium after “ecstasy” ingestion. J Psychoactive Drugs. 1999;31:167‒170.
   Google Scholar
• Lee GY, Gong GW, Vrodos N, et al. ‘Ecstasy’-induced subarachnoid haemorrhage: an under-reported neurological complication? J Clin Neurosci. 2003;10:705‒707.
   Google Scholar
• Davies O, Batajoo-Shrestha B, Sosa-Popoteur J, et al. Full recovery after severe serotonin syndrome, severe rhabdomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA. Heart Lung. 2014;43:117‒119.
   Google Scholar
• Nadkarni GN, Hoskote SS, Piotrkowski J, et al. Serotonin syndrome, disseminated intravascular coagulation, and hepatitis after a single ingestion of MDMA in an Asian woman. Am J Ther. 2014;21:e117‒119.
   Google Scholar
• Ghatol A, Kazory A. Ecstasy-associated acute severe hyponatremia and cerebral edema: a role for osmotic diuresis? J Emerg Med. 2012;42:e137‒140.
   Google Scholar
• Yang J, Jamei M, Heydari A, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol. 2006;20:842‒849.
   Google Scholar
• Eldehni MT, Roberts IS, Naik R, et al. Case report of ecstasy-induced renal venous thrombosis. NDT Plus. 2010;3:459‒460.
   Google Scholar
• Caballero F, Lopez-Navidad A, Cotorruelo J, et al. Ecstasy-induced brain death and acute hepatocellular failure: multiorgan donor and liver transplantation. Transplantation. 2002;74:532‒537.
   Google Scholar
• Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;85:E10.
   Google Scholar
• Parrott AC. Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiol. 2009;60:148‒158.
   Google Scholar
• Copeland J, Dillon P, Gascoigne M. Ecstasy and the concomitant use of pharmaceuticals. Addict Behav. 2006;31:367‒370.
   Google Scholar
• Pilgrim JL, Gerostamoulos D, Woodford N, et al. Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int. 2012;215:184‒188.
   Google Scholar
• Salathe C, Blanc AL, Tagan D. SIADH and water intoxication related to ecstasy. BMJ Case Rep. 2018;2018;pii: bcr-2018-224731.
   Google Scholar
• Armitage MC, Bryant RJ, Page CB. Severe hyponatremia complicated by seizure following 3,4-methylenedioxymethamphetamine ingestion. Emerg Med Australas. 2018;30:730‒731.
   Google Scholar
• Campbell GA, Rosner MH. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol. 2008;3:1852‒1860.
   Google Scholar
• Rosenson J, Smollin C, Sporer KA, et al. Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med. 2007;49:164‒71,171.e1.
   Google Scholar
• Budisavljevic MN, Stewart L, Sahn SA, et al. Hyponatremia associated with3,4-methylenedioxymethylamphetamine (“Ecstasy”) abuse. Am J Med Sci. 2003;326:89‒93.
   Google Scholar
• Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after “ecstasy” (3,4-MDMA). Lancet. 1996;347:1052.
   Google Scholar
• Ajaelo I, Koenig K, Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med. 1998;5:839‒840.
   Google Scholar
• Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol. 2006;20:188‒193.
   Google Scholar
• Couchman L, Frinculescu A, Sobreira C, et al. Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 - A potential risk to users? Drug Test Anal. 2019;11:1172‒1182.
   Google Scholar
• Vidal Giné C, Ventura Vilamala M, Fornís Espinosa I, et al. Crystals and tablets in the Spanish ecstasy market 2000-2014: are they the same or different in terms of purity and adulteration? Forensic Sci Int. 2016;263:164‒168.
   Google Scholar
• Peck Y, Clough AR, Culshaw PN, et al. Multi-drug cocktails: impurities in commonly used illicit drugs seized by police in Queensland, Australia. Drug Alcohol Depend. 2019;201:49‒57.
   Google Scholar
• Palamar JJ, Acosta P, Le A, et al. Adverse drug-related effects among electronic dance music party attendees. Int J Drug Policy. 2019;73:81‒87.
   Google Scholar
• Calle P, Maudens K, Lemoyne S, et al. Lessons to be learned from toxicological analyses in intoxicated patients and seized materials at an electronic music dance festival. Forensic Sci Int. 2019;299:174‒179.
   Google Scholar
• Calle P, Sundahl N, Maudens K, et al. Medical emergencies related to ethanol and illicit drugs at an annual, nocturnal, indoor, electronic dance music event. Prehosp Disaster Med. 2018;33:71‒76.
   Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2013 national survey on drug use and health: summary of national findings. [cited 2020 Jan 29]. Avalaible from: https://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf
   Google Scholar
• Pilgrim JL, Gerostamoulos D, Drummer OH. Deaths involving serotonergic drugs. Forensic Sci Int. 2010;198:110‒117.
   Google Scholar
• Vuori E, Henry JA, Ojanperä I, et al. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction. 2003;98:365‒368.
   Google Scholar
• Smilkstein MJ, Smolinske SC, Rumack BH. A case of MAO inhibitor/MDMAinteraction: agony after ecstasy. J Toxicol Clin Toxicol. 1987;25:149‒159.
   Google Scholar
• Papaseit E, Vázquez A, Pérez-Mañá C, et al. Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV). Intensive Care Med. 2012;38:1239‒1240.
   Google Scholar
• Harrington RD, Woodward JA, Hooton TM, et al. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med. 1999;159:2221‒2224.
   Google Scholar
• Henry JA, Fallon JK, Kicman AT, et al. Low-dose MDMA (“ecstasy”) induces vasopressin secretion. Lancet. 1998;351:1784.
   Google Scholar
• Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32:194‒209.
   Google Scholar
• Abbott KL, Flannery PC, Gill KS, et al. Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metab Rev. 2020;52:44‒65.
   Google Scholar
• Michael White C. How MDMA’s pharmacology and pharmacokinetics drive desired effects and harms. J Clin Pharmacol. 2014;54:245‒252.
   Google Scholar
• Mohamed WM, Ben Hamida S, Cassel JC, et al. MDMA: interactions with other psychoactive drugs. Pharmacol Biochem Behav. 2011;99:759‒774.
   Google Scholar
• Copeland J, Dillon P, Gascoigne M. Ecstasy and the concomitant use of pharmaceuticals. Addict Behav. 2006;31:367‒370.
   Google Scholar
• Pilgrim JL, Gerostamoulos D, Drummer OH. Deaths involving MDMA and the concomitant use of pharmaceutical drugs. J Anal Toxicol. 2011;35:219‒226.
   Google Scholar
• Farré M, Abanades S, Roset PN, et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther. 2007;323:954‒962.
   Google Scholar
• Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J Psychopharmacol. 2000;14:269‒274.
   Google Scholar
• Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2007;189:565‒573.
   Google Scholar
• Battaglia G, Brooks BP, Kulsakdinun C, et al. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol. 1988;149:159‒163.
   Google Scholar
• Koch S, Galloway MP. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm (Vienna). 1997;104:135‒146.
   Google Scholar
• Baumann MH, Rothman RB. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol. 2009;88:257‒296.
   Google Scholar
• Hysek CM, Simmler LD, Nicola VG, et al. Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One. 2012;7:e36476. .
   Google Scholar
• Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther. 2011;90:246‒255. .
   Google Scholar
• Schmid Y, Rickli A, Schaffner A, et al. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol ExpTher. 2015;353:102111.
   Google Scholar
• Segura M, Farré M, Pichini S, et al. Contribution of cytochrome P4502D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet. 2005;44:649‒660.
   Google Scholar
• de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, et al. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet. 2012;3:235.
   Google Scholar
• Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA (“Ecstasy”) after haloperidol pretreatment in healthy humans. EurNeuropsychopharmacol. 2000;10:289‒295.
   Google Scholar
• Hysek CM, LD S, NM S, et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol. 2014;17:371‒381.
   Google Scholar
• de Sousa Fernandes Perna EB, Theunissen EL, Kuypers KP, et al. Memory and mood during MDMA intoxication, with and without memantine pretreatment. Neuropharmacology. 2014;87:198‒205.
   Google Scholar
• vanWel JH, Kuypers KP, Theunissen EL, et al. Blockade of 5-HT2 receptor selectively prevents MDMA-induced verbal memory impairment. Neuropsychopharmacology. 2011;36:1932‒1939.
   Google Scholar
• Hysek CM, Vollenweider FX, Liechti ME. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emerg Med J. 2010;27:586‒589.
   Google Scholar
• Hysek C, Schmid Y, Rickli A, et al. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol. 2012;166:2277‒2288.
   Google Scholar
• Hysek CM, Brugger R, Simmler LD, et al. Effects of the α2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers. J Pharmacol Exp Ther. 2012;340(2):286‒294.
   Google Scholar
• Hysek CM, Fink AE, Simmler LD, et al. α₁-Adrenergic receptors contribute to the acute effects o f3,4-methylenedioxymethamphetamine in humans. J Clin Psychopharmacol. 2013;33(5):658‒666.
   Google Scholar
• Haijen E, Farre M, de la Torre R, et al. Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. Psychopharmacology (Berl). 2018;235(3):709‒717.
   Google Scholar
• Kuypers KPC, de la Torre R, Farre M, et al. indifference to negative sounds is mediated by the 5-HT(2A)receptor. Psychopharmacology (Berl). 2018;235:481‒490.
   Google Scholar
• Liechti ME, Saur MR, Gamma A, et al. Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000;23(4):396‒404.
   Google Scholar
• Taylor CP, Traynelis SF, Siffert J, et al. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016;164:170‒182.
   Google Scholar
• Yubero-Lahoz S, Pardo R, Farré M, et al. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet. 2011;50(5):319‒329.
   Google Scholar
• Halkitis PN, Green KA. Sildenafil (Viagra) and club drug use in gay and bisexual men: the role of drug combinations and context. Am J Mens Health. 2007;1(2):139‒147.
   Google Scholar
• Breslau K. The ‘sextasy’ craze. Clubland’s dangerous party mix: viagra and ecstasy. Newsweek. 2002;139:30.
   Google Scholar
• Morefield KM, Keane M, Felgate P, et al. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users. Addiction. 2011;106(7):1293‒1300.
   Google Scholar
• Peiró AM, Farré M, Roset PN, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. Psychopharmacology (Berl). 2013;225(4):883‒893. .
   Google Scholar
• Farré M, Tomillero A, Pérez-Mañá C, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart. Eur Neuropsychopharmacol. 2015;25:1637‒1649. .
   Google Scholar
• Farré M, de la Torre R, Mathúna BO, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl). 2004;173:364‒375. .
   Google Scholar
• Kuypers KP, Wingen M, Ramaekers JG. Memory and mood during the night and in the morning after repeated evening doses of MDMA. J Psychopharmacol. 2008;22:895‒903.
   Google Scholar
• Costardi JV, Nampo RA, Silva GL, et al. A review on alcohol: from the central action mechanism to chemical dependency. Rev Assoc Med Bras (1992). 2015;61:381‒387.
   Google Scholar
• Kuypers KP, Wingen M, Samyn N, et al. Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night. Psychopharmacology (Berl). 2007;192:111‒119.
   Google Scholar
• Hernández-López C, Farré M, Roset PN, et al. 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther. 2002;300(1):236‒244.
   Google Scholar
• Kuypers KP, Samyn N, Ramaekers JG. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology (Berl). 2006;187(4):467‒475.
   Google Scholar
• Dumont GJ, Kramers C, Sweep FC, et al. Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology. J Psychopharmacol. 2010;24(2):165‒174.
   Google Scholar
• Dumont GJ, Schoemaker RC, Touw DJ, et al. Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. J Psychopharmacol. 2010;24(2):155‒164.
   Google Scholar
• Schulz S. MDMA & cannabis: a mini-review of cognitive, behavioral, and neurobiological effects of co-consumption. Curr Drug Abuse Rev. 2011;4:81‒86.
   Google Scholar
• Dumont GJ, Wezenberg E, Valkenberg MM, et al. Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteers. Psychopharmacology (Berl). 2008;197(3):465‒474.
   Google Scholar
• Dumont GJ, Kramers C, Sweep FC, et al. Cannabis coadministration potentiates the effects of “ecstasy” on heart rate and temperature in humans. Clin Pharmacol Ther. 2009;86(2):160–166. .
   Google Scholar
• Peacock A, Bruno R, Ferris J, et al. Energy drink use frequency among an international sample of people who use drugs: associations with other substance use and well-being. Drug Alcohol Depend. 2017;174:70‒79.
   Google Scholar
• Peacock A, Sindicich N, Dunn M, et al. Co-ingestion of energy drinks with alcohol and other substances among a sample of people who regularly use ecstasy. Drug and Alcohol Review. 2016;35(3):352‒358.
   Google Scholar
• Togni LR, Lanaro R, Resende RR, et al. The variability of ecstasy tablets composition in Brazil. J Forensic Sci. 2015 Jan;60(1):147‒151. .
   Google Scholar
• Yubero-Lahoz S, Pardo R, Farre M, et al. Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. Drug Metab Pharmacokinet. 2012;27:605‒613.
   Google Scholar